Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) gave a pipeline update noting that it intends to complete its Perifosine Phase 3 study in metastatic colorectal cancer in March 2012, and release top-line data release within several weeks thereafter. It expects to complete its long-term Phase 3 study of Zerenex in 4Q 2012.
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) gave a pipeline update, maintaining previous guidance that it expects data from its Phase 3 trial of Palifosfamide in patients with metastatic soft tissue sarcoma, during 2H 2012. A Phase 3 trial of Palifosfamide in front-line, extensive SCLC is expected to be initiated in 2H 2012. It also expects to initiate a Phase 2 study of Interleukin-12 (IL-12) in 2H 2012.
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) gave an update of its Phase 2b trial of ganetespib results in non-small cell lung cancer (NSCLC) patients noting that enrollment is expected to be completed in 2Q 2012 with interim results, including landmark PFS, response rate, and disease control rates also expected in 2Q 2012. Final progression-free survival results, as well as overall survival results, are expected in 2H of 2012.
Isis Pharmaceuticals, Inc.(Nasdaq: ISIS) maintained guidance that it expects to file its NDA for KYNAMRO (Mipomersen) during 1Q 2012 for patients with homozygous Familial Hypercholesterolemia (FH).
VIVUS, Inc. (Nasdaq:VVUS) announced the pricing of its underwritten public offering of 9m shares of its common stock at a price to the public of $22.50 per share for gross proceeds of approximately $202.5 million and an option to issue a further 1.35m additional shares.
Nektar Therapeutics (Nasdaq: NKTR) announced that it will sell Royalty Pharma its royalties on future sales of CIMZIA, under Nektar’s agreement with UCB Pharma, and MIRCERA®, under Nektar’s agreement with Roche, in return for a cash payment of $124.0 million.